What are your management strategies for patients with chronic kidney disease attributed to deferasirox use who require frequent blood products for a hematologic disorder?

It depends on the type and severity of the hematological disorder as well as the extent of CKD. Currently, two oral chelators; deferasirox and deferiprone, are available, in addition to deferoxamine, which can be administered SubQ or IV. These can be mixed and combined, and combination therapy may b...